404 related articles for article (PubMed ID: 19286225)
1. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2009 May; 181(5):1998-2006; discussion 2007-8. PubMed ID: 19286225
[TBL] [Abstract][Full Text] [Related]
2. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of androgen deprivation therapy.
Choi SM; Kam SC
Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
[TBL] [Abstract][Full Text] [Related]
4. [Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone].
Terrier JE; Mottet N
Prog Urol; 2013 Feb; 23(2):88-95. PubMed ID: 23352300
[TBL] [Abstract][Full Text] [Related]
5. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications.
Tzortzis V; Samarinas M; Zachos I; Oeconomou A; Pisters LL; Bargiota A
Hormones (Athens); 2017 Apr; 16(2):115-123. PubMed ID: 28742500
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy for prostate cancer: new concepts and concerns.
Smith MR
Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):247-54. PubMed ID: 17940447
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.
Saylor PJ; Keating NL; Smith MR
J Gen Intern Med; 2009 Nov; 24 Suppl 2(Suppl 2):S389-94. PubMed ID: 19838837
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
11. Emerging cardiometabolic complications of androgen deprivation therapy.
Choong K; Basaria S
Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
Miller K
Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.
Saylor PJ; Smith MR
J Natl Compr Canc Netw; 2010 Feb; 8(2):211-23. PubMed ID: 20141678
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risks of androgen deprivation therapy.
Ribeiro AF; Camara C; Segre CA; Srougi M; Serrano CV
Arq Bras Cardiol; 2010 Sep; 95(3):412-5. PubMed ID: 20944900
[TBL] [Abstract][Full Text] [Related]
16. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
Leahy Y
Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
[TBL] [Abstract][Full Text] [Related]
17. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.
Østergren PB; Kistorp C; Fode M; Bennedbaek FN; Faber J; Sønksen J
BJU Int; 2019 Apr; 123(4):602-611. PubMed ID: 30388320
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
19. [Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review].
Klemm J; von Deimling M; Fisch M; Kramer G; Tilki D; Steuber T; von Amsberg G; Hengstenberg C; Shariat SF
Urologie; 2024 Mar; 63(3):262-268. PubMed ID: 37874334
[TBL] [Abstract][Full Text] [Related]
20. Uncovering the metabolic complications of androgen deprivation therapy in patients with prostate cancer--where do we take it next?
Pinthus JH
J Urol; 2015 Jun; 193(6):1882-3. PubMed ID: 25794833
[No Abstract] [Full Text] [Related]
[Next] [New Search]